Drug Profile
Research programme: anti-HER2/HER3 bispecific antibody - Biocad
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Biocad
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action ERBB 2 receptor antagonists; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in Russia (Parenteral)